HighGravityDataSigned in · PRO
Guidance history, every release
Raised · a change from the previous releaseSame · restated unchanged— · not stated in that releaseEvery value links to its sentence in the filing
| Metric | May 8, 2024 FY24 Q1 | Jul 31, 2024 FY24 Q2 | Nov 5, 2024 FY24 Q3 | Jan 12, 2025 FY24 Q4 | May 1, 2025 FY25 Q1 | Aug 6, 2025 FY25 Q2 | Nov 3, 2025 FY25 Q3 | Feb 13, 2026 FY25 Q4 |
|---|---|---|---|---|---|---|---|---|
| For FY2025 | ||||||||
| Precision Oncology revenue | — | — | — | — | — | New“$690 - $700 million” | — | — |
| Precision Oncology revenue Y/Y growth rate | — | — | — | — | — | New“6%” | — | — |
| Revenue midpoint increase | — | — | — | — | — | — | New“$78 million” | — |
| Screening revenue | — | — | — | — | — | New“$2.440 - $2.470 billion” | — | — |
| Screening revenue Y/Y growth rate | — | — | — | — | — | New“17%” | — | — |
| Total revenue | — | — | — | — | New“$3.070 - $3.120 billion” | Raised“$3.130 - $3.170 billion” | Raised“$3.220 - $3.235 billion” | — |
| Total revenue Y/Y growth rate | — | — | — | — | — | New“14%” | Raised“17%” | — |
| Adjusted EBITDA | — | — | — | — | New“$425 - $455 million” | Raised“$455 - $475 million” | Raised“$470 - $480 million” | — |
| Adjusted EBITDA midpoint increase | — | — | — | — | — | — | New“$10 million” | — |
| Adjusted EBITDA Y/Y growth rate | — | — | — | — | — | New“44%” | Raised“47%” | — |
| Precision Oncology | — | — | — | — | New“$680 - $695 million” | — | Raised“$710 - $715 million” | — |
| Precision Oncology Y/Y growth rate | — | — | — | — | — | — | New“9%” | — |
| Screening | — | — | — | — | New“$2.390 - $2.425 billion” | — | Raised“$2.510 - $2.520 billion” | — |
| Screening Y/Y growth rate | — | — | — | — | — | — | New“20%” | — |
| For FY2024 | ||||||||
| Precision Oncology revenue | New“$655-$675 million” | — | — | — | — | — | — | — |
| Revenue | — | — | — | New“$713 million” | — | — | — | — |
| Revenue | New“$2.810-$2.850 billion” | — | — | — | — | — | — | — |
| Screening revenue | New“$2.155-$2.175 billion” | — | — | — | — | — | — | — |
| Total revenue | New“$2.810 - $2.850 billion” | Reiterated“$2.810 - $2.850 billion” | Lowered“$2.730 - $2.750 billion” | — | — | — | — | — |
| Adjusted EBITDA | — | New“$335 - $355 million” | Lowered“$310 - $320 million” | — | — | — | — | — |
| Adjusted EBITDA midpoint raise | — | New“$8M” | — | — | — | — | — | — |
| Precision Oncology | — | New“$655 - $675 million” | Lowered“$650 - $655 million” | — | — | — | — | — |
| Screening | — | New“$2.155 - $2.175 billion” | Lowered“$2.080 - $2.095 billion” | — | — | — | — | — |
| No period stated | ||||||||
| Multi-year productivity plan annual savings target | — | — | — | — | — | New“$150 million in annual savings by 2026” | — | — |
| Precision Oncology | — | — | — | — | — | New“$690 - $700 million” | — | — |
| Screening | — | — | — | — | — | New“$2.440 - $2.470 billion” | — | — |
Values in quotation marks are the company’s words. Change labels compare each statement with the same metric and target year in the previous release. HighGravityData does not judge whether guidance was met.